Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.55 |
| ▸ | HRH2 | P25021 | 7/20 | 0.55 |
| ▸ | HRH1 | P35367 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559203 | 1.00 | SIGMAR1 (0.56) | SIGMAR1MEN1KMT2AHRH3HRH2 | |
| SCHEMBL3564647 | 0.96 | MEN1 (0.48) | SIGMAR1MEN1KMT2AHRH3HRH2 | |
| SCHEMBL2335855 | 0.88 | HRH3 (0.68) | SIGMAR1MEN1HRH3HRH2HRH1 | |
| SCHEMBL1723767 | 0.84 | HRH3 (0.54) | SIGMAR1HRH3HRH2HRH1 | |
| SCHEMBL1714467 | 0.83 | HRH3 (0.68) | SIGMAR1MEN1HRH3HRH2HRH1 | |
| SCHEMBL3562862 | 0.81 | HRH3 (0.62) | SIGMAR1MEN1KMT2AHRH3HRH2 | |
| SCHEMBL3564027 | 0.81 | CHEK1 (0.50) | — | |
| SCHEMBL7246784 | 0.81 | HRH3 (0.63) | HRH3HRH2HRH1 | |
| Water SCHEMBL2903086 | 0.81 | HRH3 (0.66) | SIGMAR1MEN1KMT2AHRH3HRH2 | |
| SCHEMBL3560997 | 0.81 | HRH3 (0.66) | SIGMAR1MEN1KMT2AHRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993603-B2 | Pharmaceutical composition and method using antifungal agent in combination | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993603-B2 | Pharmaceutical composition and method using antifungal agent in combination | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| EP-1767526-B1 | ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO LTD (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-1767526-B1 | ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO LTD (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-7700623-B2 | Arylamidine derivative, salt thereof, and antifungal containing these | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-7700623-B2 | Arylamidine derivative, salt thereof, and antifungal containing these | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1867332-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1767526-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF, AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-1767526-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF, AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | PIK3C3, ARSA, ACR | SIGMAR1 2443/4885MEN1 1261/4885KMT2A 3740/4885 |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | NAT1, ERG28, SLC7A1 | SIGMAR1 1661/4885MEN1 664/4885KMT2A 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.